Placebo News and Research

RSS

UC Davis computer model can test effects of anti-arrhythmia medications

UC Davis researchers have developed an accurate computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.

2 Sep 2011

Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia

Dr. Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.

2 Sep 2011

New meta-analysis reaffirms safety profile of aspirin for pain relief, fever

A new meta-analysis published this week in Drugs in R&D, reaffirms the safety profile of aspirin for short-term treatment of mild to moderate pain, and aches and fever due to colds when used as directed.

2 Sep 2011

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

A new medication to treat major depressive disorder in patients who have not responded to other antidepressants is being studied in a Phase II clinical trial by researchers at The University of Texas Health Science Center at Houston.

2 Sep 2011

Further acne treatment studies necessary: Experts

Researchers writing in the journal The Lancet suggest further research that is urgently needed for effective non-antibiotic treatments for acne, because of concerns regarding long-term antibiotic use and its contribution to bacterial resistance. Pharmacies are well stocked with a wide range of acne medications. However, evidence regarding their efficacy and which treatments work best for whom are limited, the authors added.

31 Aug 2011

Eisai announces results of perampanel Phase III study on epilepsy

Results presented today of a Phase III pivotal study for the investigational compound perampanel for partial-onset seizures showed that perampanel, 8 mg and 12 mg, produced statistically significant reductions in median seizure frequency compared to placebo among patients having partial-onset seizures while receiving treatment with one to three other epilepsy drugs.

31 Aug 2011

Comprehensive review on non-drug interventions for treatment of high blood pressure

More and more, patients show up to appointments with hypertension expert John Bisognano, M.D., Ph.D. carrying bags full of "natural" products that they hope will help lower their blood pressure. And like most physicians, Bisognano doesn't always know if these products will do any good, or if they will cause any harm.

31 Aug 2011

Yoga as therapy in neuropsychiatric disorders

Yoga is commonly seen as a practice beneficial to body and mind. Increasingly, yoga is being taken a step further and applied as a form of complementary and alternative medicine in treating psychiatric disorders.

31 Aug 2011

Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the positive results from the completion of their tolerability trial of Menerba (MF101) for menopausal hot flashes.

31 Aug 2011

Positive results from Pearl's formoterol fumarate MDI Phase 2b trial on moderate-to-severe COPD

Pearl Therapeutics Inc. today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil Aerolizer in patients with moderate-to-severe COPD.

31 Aug 2011

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.

30 Aug 2011

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

30 Aug 2011

Vitamin A supplements could save the lives of 600,000 children a year, researchers say

"Giving vitamin A supplements to children under the age of five in developing countries could save 600,000 lives a year, researchers claim" in a paper published Thursday in the British Medical Journal, BBC News reports.

30 Aug 2011

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

Ivabradine reduces heart volume among patients with cardiac insufficiency

As guest speaker at the European Society of Cardiology's Congress currently under way in Paris, Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute's Research Centre and professor of medicine at the Universit- de Montr-al, today presented the results of an analysis demonstrating that ivabradine, a medication used to reduce heart rate, also reduces heart volume (left ventricle) among patients with cardiac insufficiency.

30 Aug 2011

Vitamin A supplements in children could save up to 600,000 lives a year: Study

Researchers have found that giving vitamin A supplements to children under the age of five in developing countries could save up to 600,000 lives a year. Writing in the British Medical Journal, UK and Pakistani experts assessed 43 studies involving 200,000 children, and found deaths were cut by 24% if children were given the vitamin. They add that it would also cut rates of measles and diarrhea.

30 Aug 2011

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Today, Bayer Inc. announced the Health Canada approval of STAXYN, the first orally disintegrating tablet for the treatment of erectile dysfunction (ED) that lasts up to eight hours.

29 Aug 2011

Statins protect people against death from respiratory illness, infections

The death rate among patients prescribed a statin in a major trial that ended in 2003 is still lower than those given a placebo, even though most participants in both groups have been taking statins ever since. ASCOT, the Anglo-Scandinavian Cardiac Outcomes Trial, was stopped early because the statin was so effective at preventing heart attacks and strokes, but a new analysis has shown that eight years on, the most significant difference between the groups is a reduction in deaths from infection and respiratory illness.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

Colchicine more effective than placebo for recurrent pericarditis

Colchicine, when given in addition to conventional therapy, was more effective than placebo in reducing the incidence of recurrence and the persistence of symptoms of pericarditis in a randomised controlled trial.

29 Aug 2011